• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » Science » Targeted therapy

Targeted therapy
Targeted therapy RSS Feed RSS

Cancer

Discovery of novel KRAS G12C inhibitor with promising in vivo efficacy and safety

Sep. 21, 2022
Researchers from Sun Yat-sen University, Southern Medical University and Gannan Medical University reported the discovery of novel quinazoline-based KRAS G12C inhibitors as potential anticancer agents.
Read More
Cancer cells
Cancer

TYRA-300 retains potency in presence of gatekeeper resistance mutation

Sep. 21, 2022
Researchers from Tyra Biosciences Inc. presented a novel FGFR3-selective inhibitor agnostic to the gatekeeper mutation, named TYRA-300.
Read More
Cancer cells under magnifying glass
Cancer

EED inhibitor HJM-353 shows antitumor activity in preclinical models of cancer

Sep. 19, 2022
Polycomb repressive complex 2 (PRC2) is composed of several subunits, such as EZH2, EED and SUZ12, and is a regulator of cell proliferation and development. Targeting the allosteric subunit EED may be a new approach for fully inhibiting PRC2 complex activity and addressing the limitations of EZH2 inhibition.
Read More
Cancer cells.
Cancer

PARP-1 decoy OX-413 promotes tumor cell metabolic exhaustion

Sep. 16, 2022
Poly (ADP-ribose) polymerase (PARP) inhibitors promote significant anticancer effects against homologous recombination-defective (HRD) tumors but have limited efficacy against homologous recombination proficient (HRP) cancers.
Read More
Human NK cell
Immuno-oncology

CYT-303 antibody promotes tumor NK-cell infiltration in HCC model

Sep. 16, 2022
GPC3 is an oncofetal antigen highly expressed in hepatocellular carcinoma (HCC) but minimally expressed in adult normal tissues, except the placenta. Cytovia Therapeutics Inc. has presented preclinical data on CYT-303, a bispecific natural killer (NK) engager targeting NK cell-activating receptor NKp46 and GPC3 expressed in tumor cells.
Read More
Cancer

PRAME-targeting IMA-402 TCER shows promise for treating solid tumors

Sep. 15, 2022
Researchers from Immatics Biotechnologies GmbH have developed bispecific T-cell engaging receptor (TCER) molecules consisting of an affinity maturated TCR, a humanized T cell-recruiting antibody and an Fc-part conferring half-life extension and favorable stability characteristics.
Read More
Cancer cell
Cancer

Arginase inhibitor OATD-02 shows promise in cancer treatment

Sep. 15, 2022
Arginases play key roles in metabolic pathways. Arginase 1 (ARG1) is expressed by myeloid cells in the tumor microenvironment and suppresses the functioning of T and NK cells.
Read More
Cancer

Novartis presents new RET inhibitors for lung adenocarcinoma

Sep. 14, 2022
Proto-oncogene tyrosine-protein kinase receptor Ret is a widely expressed oncogene and chromosomal rearrangements involving RET lead to fusion genes and RET kinase activation, which occur in lung cancer in about in 2% of cases of non-small cell lung cancer.
Read More
Lung cancer illustration
Cancer

BI-4142 and BI-1622 show efficacy against HER2 exon 20 insertion-driven tumors, while preserving EGFR wt signaling

Sep. 14, 2022
Boehringer Ingelheim Pharma GmbH & Co KG has presented data on the identification of several potent and selective tyrosine kinase inhibitors (TKIs) of HER2 that are highly active against its oncogenic exon 20 YVMA insertion mutant (HER2 YVMA), which is the most prevalent HER2 exon 20 mutation in non-small-cell lung cancer (NSCLC).
Read More
Neurology/Psychiatric

Targeting ApoB100 rescues motor neuron degeneration in ALS

Sep. 13, 2022
Amyotrophic lateral sclerosis (ALS) is a progressive disease characterized by upper and lower motor neuron degeneration.
Read More
Previous 1 2 3 4 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 11, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • Incurix describes new c-Myc inhibitors

    BioWorld Science
    Incurix Co. Ltd. has identified Myc proto-oncogene protein (c-Myc) inhibitors reported to be useful for the treatment of cancer.
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe